x
- Home
- Diabetes Models
- In Vivo Models of Diabetes Mellitus
- In Vitro Models of Diabetes Mellitus
- Diabetes Drug R&D Services
- Therapeutic Areas
- Virtual Booth
- Company
Accurate biomarkers reflecting insulin resistance are critical. Ace Therapeutics is committed to applying our expertise and platform technologies to help our clients develop more accurate biomarkers related to insulin resistance and to help them progress in the development of antidiabetic drugs targeting IR therapies.
Mechanistically, any factor that leads to an abnormality in the insulin signaling pathway contributes to the development of insulin resistance (IR) in the patients, including insulin receptor abnormalities, disturbances in the internal environment (regarding inflammation, hypoxia, lipotoxicity, and immunity), metabolic function of the liver and organelles, and other abnormalities. Potential biomarkers that have been identified in relation to insulin resistance, including adiponectin, RBP4, chemerin, FABP4, FGF21, fetuin-A, myostatin, IL-6, and irisin, all of which may play significant roles in determining insulin sensitivity.
Ace Therapeutics' team of biomarker experts has experience across various diabetes areas. Our biomarker laboratory supports the discovery and validation of insulin resistance-related biomarkers with various techniques and state-of-the-art equipment. With a personalized focus, our full range of services covers the support needed to take your antidiabetic drug development to the next stage.
We offer two modes of insulin-related biomarker discovery services. One enables the discovery of new, previously unknown insulin-related biomarkers and provides a comprehensive understanding of biological systems. We support the discovery of insulin resistance-related biomarkers by screening a variety of high-throughput samples for potential markers while identifying potential biomarkers with the help of bioinformatics analyses. In addition, we can identify biomarkers that have been suspected to be associated with insulin resistance, and may lead to more rapid validation of biomarkers.
We validate insulin-related biomarkers using a combination of in vivo and in vitro studies. Our integrated approach can reduce trial costs and shorten trial times, providing insights for the development of novel insulin-related biomarkers.
Ace Therapeutics' cutting-edge biomarker development platform is equipped with multi-omics technologies. These advanced technologies enable us to provide our clients with reliable data and support in the discovery of biomarkers related to insulin resistance.
| Technologies | Introduction |
|---|---|
| Gene expression profiling technology | We identify gene expression markers associated with insulin resistance and diabetes by analyzing changes in gene expression levels in different tissues and cells. |
| Metabolomics analysis technology | We identify metabolic markers associated with insulin resistance and diabetes by analyzing changes in metabolite levels in blood, urine, or tissue. |
| Proteomic analysis technology | We identify protein markers associated with insulin resistance and diabetes by analyzing changes in protein expression levels in different tissues or cells. |
| Functional genomics analysis technology | We study the function of genes to identify genetic variants or abnormalities in gene expression associated with insulin resistance and diabetes. |
Ace Therapeutics' biomarker discovery services provide excellent support to help you maximize your sample analysis. Our team of experts is dedicated to providing you with solutions that meet your needs. We use cutting-edge technology to ensure you get accurate results that are reliable and reproducible. Please feel free to contact us for more details.
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
